Related Experiment Video
Updated: Sep 12, 2025

Retinal Pathophysiological Evaluation in a Rat Model
Published on: May 6, 2022
Hypoglycaemic Principles of Securidaca longepedunculata Extracts Reverses Experimental Diabetes and Diabetes
Obiora Emmanuel Abonyi1, John Onyebuchi Ogbodo2, Simeon Ikechukwu Egba3
1Department of Medical Biochemistry College of Medicine, Enugu State University of Science and Technology, Agbani, Enugu, Nigeria.
Abstract:
Background: This study investigated the effect of the extractable hypoglycaemic principles from Securidaca longepedunculata leaves on some biochemical parameters in alloxan-induced diabetic rats with the view to having improved pharmacological agent(s) that could be used in managing diabetes mellitus with relatively lesser side effects. Three groups of four rats each were used for the oral glucose tolerance test (OGTT): group one received 3 mL/kg BW normal saline (normal control) while groups 2 and 3 received 200 and 400 mg/kg BW of methanol extract of Securidaca longepedunculata (MESL), respectively. Six groups of five rats per group were used for the main antidiabetic study. Group one received 3 mL/kg BW normal saline (normal control), group 2 received no treatment after induction, group 3, received 5 mg/kg BW glibenclamide (standard group), groups 3-6 received 100, 200, and 400 mg/kg BW MESL, respectively, after induction. Results: The OGTT showed significant (p < 0.05) reduction in random blood sugar of the treated groups compared to the control. In the antidiabetic study, the treated groups 4-6 significantly (p < 0.05) lowered the blood glucose of the Wistar rats compared to the treatment control. Extract administration showed no adversity to liver and kidney, respectively, as shown by result of tested standard indicators. Equally MESL caused significant (p < 0.05) increase in serum antioxidant activities and significant (p < 0.05) decrease in malondialdehyde concentration compared to the treatment control. Conclusion: The study suggested hypoglycaemic potency, antioxidant rejuvenation, and relative hepatic and nephron safety by MESL.
Related Concept Videos
Hypoglycemia and Glucagon
Glucagon-like Receptor Agonists
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
Oral Hypoglycemic Agents: Glinides
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
Acarbose and miglitol are...
Diabetes Mellitus: Overview and Type I Subtype
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
Diabetes: Symptoms, Diagnosis, and Complications

